This poster is published under an
open license. Please read the
disclaimer for further details.
Type:
Educational Exhibit
Keywords:
Diagnostic procedure, Nuclear medicine conventional, PET-CT, PET, Lymph nodes, Neoplasia
Authors:
I. López-Vidaur1, A. Santiago Chinchilla2, N. Testar Dardel3, F. Cordido3, L. I. Armendariz Blanco3, I. Rozas Gómez3, T. M. Garcia3, E. agrela3; 1Madrid/ES, 2Granada/ES, 3Alcorcón/ES
DOI:
10.1594/ecr2015/C-0154
References
- Fletcher,
James W.,
et al.
"Recommendations on the use of 18F-FDG PET in oncology." Journal of Nuclear Medicine 49.3 (2008): 480-508.
- Moulin-Romsee,
Gerard,
et al.
"18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging." European journal of nuclear medicine and molecular imaging 37.6 (2010): 1095-1105.
- Antoch,
Gerald,
et al.
"To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT." Journal of Nuclear Medicine 45.1 suppl (2004): 56S-65S.
- Delbeke,
Dominique,
et al.
"Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0." Journal of Nuclear Medicine 47.5 (2006): 885-895.
- Tatsumi,
Mitsuaki,
et al.
"Direct Comparison of FDG PET and CT Findings in Patients with Lymphoma: Initial Experience 1." Radiology 237.3 (2005): 1038-1045.
- Jhanwar,
Yuliya S.,
and David J.
Straus.
"The role of PET in lymphoma."Journal of Nuclear Medicine 47.8 (2006): 1326-1334.